U.S. Tobacco Stock News

NasdaqCM:CMPX
NasdaqCM:CMPXBiotechs

A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance

Clinical milestones and earnings set the context for Compass Therapeutics stock Compass Therapeutics (CMPX) has been in focus after reaching the planned survival event threshold in its Phase 2/3 COMPANION-002 trial for biliary tract cancer, along with FDA clearance for its CTX-10726 investigational program. These developments come as the company reported a full year 2025 net loss of US$66.49 million and a fourth quarter net loss of US$15.72 million, figures that help frame current...
NasdaqGS:VSNT
NasdaqGS:VSNTMedia

Versant Media Group (VSNT) Balances Buybacks, Dividend and Digital Pivot Is Capital Allocation Truly Aligned?

Versant Media Group, Inc. recently reported full-year 2025 results showing lower sales of about US$6.69 billion and net income of US$930 million, while its board approved a US$0.375 quarterly dividend and authorized up to US$1 billion in share repurchases. Alongside these capital return moves, management is emphasizing disciplined bolt-on acquisitions, a shift toward digital and ad-supported platforms, and maintaining a strong balance sheet as a newly independent media company. Next, we’ll...
NYSE:FVRR
NYSE:FVRRProfessional Services

Fiverr Downgrades And Investor Exit Test Confidence In Turnaround Story

Multiple analysts have downgraded Fiverr International (NYSE:FVRR), signaling a reset in sentiment around the platform's business outlook. The Optimist Fund, a major institutional investor and former top holder of FVRR, has fully exited its position. These moves come as the market focuses on Fiverr's customer acquisition challenges and pressure on active buyer trends and revenue expectations. For you as an investor, the reaction in NYSE:FVRR has been sharp. The stock closed at $11.33, with...
NasdaqCM:RGC
NasdaqCM:RGCPharmaceuticals

DOJ Probe Puts Regencell Bioscience Finances And Investor Outlook Under Strain

The U.S. Department of Justice has opened an investigation into Regencell Bioscience Holdings for potential violations of federal securities laws. Authorities have requested extensive documentation related to the company’s operations, finances, and accounting. Regencell expects substantial legal expenses and acknowledges the possibility of fines or settlements that may not be fully covered by insurance. For shareholders of Regencell Bioscience Holdings, ticker NasdaqCM:RGC, this...
NasdaqGS:JOYY
NasdaqGS:JOYYInteractive Media and Services

Is JOYY (JOYY) Pricing Reflect Its Strong DCF And P/E Signals?

If you are wondering whether JOYY's share price really reflects what the business is worth, you are not alone. This article is going to focus squarely on that question. JOYY recently closed at US$60.80, with returns of 1.9% over 7 days, a 1.8% decline over 30 days, a 6.1% decline year to date, a 33.8% gain over 1 year and a 139.0% gain over 3 years, while the 5 year return stands at a 36.6% decline. These mixed returns have kept investors focused on how sentiment around JOYY is shifting, and...
NYSE:UAA
NYSE:UAALuxury

Under Armour Taps SXSW Jacket To Highlight Sustainability And Valuation Story

UNLESS COLLECTIVE, a subsidiary of Under Armour (NYSE:UAA), has been selected as the partner for SXSW's first official Filmmakers Jacket. The collaboration centers on a plant-based, regenerative festival jacket created for SXSW's 2026 event. This represents a move for Under Armour into higher profile sustainable festival merchandise tied to a major cultural gathering. Under Armour, best known for performance athletic wear, is using UNLESS COLLECTIVE to expand into eco-focused apparel tied...
NYSE:APG
NYSE:APGConstruction

APi Group Leans On Inspection First Model To Build Cash And Scale

APi Group (NYSE:APG) reports record revenue levels alongside higher profitability. The company highlights 21 consecutive quarters of double digit inspection growth in North America. Management continues to pursue bolt on acquisitions while expanding free cash flow margins. APi Group, listed on the NYSE under the ticker APG, focuses on safety and specialty services with an inspection first model that aims to drive recurring revenue. Recent updates around record revenue, stronger...
NYSE:NOMD
NYSE:NOMDFood

Is Nomad Foods (NOMD) Starting To Look Interesting After A 47% One Year Share Price Slide

If you are wondering whether Nomad Foods at US$10.33 is starting to look like value or a value trap, you are not alone. That is exactly what this article will unpack. The stock has seen an 8.3% decline over the last week, an 18.0% drop over the past month, and is down 47.0% over the past year, putting long term holders under pressure and raising fresh questions about risk and return. Recent coverage has focused on how prolonged share price weakness and earlier acquisition activity have...
NasdaqCM:SPT
NasdaqCM:SPTSoftware

Sprout Social (SPT) Is Up 9.1% After Mixed Q4 Results and New 2026 Outlook – What’s Changed

Sprout Social recently reported fourth-quarter 2025 revenue of US$120.89 million and a net loss of US$10.74 million, alongside filing a US$23.19 million shelf registration for 3,573,414 Class A shares tied to its employee stock ownership plans. The combination of improving loss per share, new 2026 revenue guidance, and potential employee share issuance offers fresh insight into how Sprout Social is funding growth and rewarding staff while remaining unprofitable. Against this backdrop of...
NasdaqGS:TBLA
NasdaqGS:TBLAInteractive Media and Services

Taboola.com (TBLA) Valuation Check After Swing To Profit And New Revenue Guidance

Why Taboola.com (TBLA) is back on investor radar Taboola.com (NasdaqGS:TBLA) is in focus after reporting fourth quarter and full year 2025 results that shifted from a prior year net loss to net income, along with new 2026 revenue guidance. See our latest analysis for Taboola.com. The earnings release and fresh 2026 guidance have put Taboola.com back in focus, with a 1 day share price return of 6.92% and 7 day share price return of 11.11% contrasting with a weaker year to date share price...
NYSE:ACA
NYSE:ACAConstruction

Arcosa Refocuses On Infrastructure As Barge Sale Reshapes Earnings Story

Arcosa (NYSE:ACA) announced the sale of its barge business and is shifting its focus toward construction materials and engineered structures. The move is aimed at concentrating resources on U.S. infrastructure and power related businesses that management views as core to the company. Arcosa, trading at $111.28 at the last close, is coming off a strong longer term stretch, with the stock up 37.0% over the past year and 87.8% over three years. The company is also ahead 76.5% over five years,...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Progyny Adds INVO Fertility Clinic As Network Grows And Shares Lag

INVO Fertility has joined the Progyny (NasdaqGS:PGNY) provider network, adding its clinic to Progyny's fertility benefits platform. The partnership expands access to employer sponsored fertility care for patients in Wisconsin and nearby regions. This development broadens Progyny's provider footprint and increases potential touchpoints with covered employees seeking fertility treatment. Progyny runs a fertility benefits platform that connects employer sponsored health plans with a network of...
NYSE:MPT
NYSE:MPTHealth Care REITs

Medical Properties Trust Faces Prospect Bankruptcy Test For Rent Resilience

Medical Properties Trust (NYSE:MPT) has issued a response to Prospect Medical Group's bankruptcy filing. The company is outlining potential operational impacts related to Prospect's tenant status and leased hospital assets. Investors are watching for updates on rental income exposure, asset utilization, and any changes to existing lease arrangements. Medical Properties Trust focuses on owning and leasing hospital and healthcare facilities, so any disruption involving a key tenant like...
NasdaqGS:AARD
NasdaqGS:AARDPharmaceuticals

A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves

Aardvark Therapeutics (AARD) has put its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome on hold after reversible cardiac issues at higher doses, triggering delays, legal scrutiny, and sharp share price swings. See our latest analysis for Aardvark Therapeutics. The HERO trial pause has been the clear driver of volatility, with Aardvark Therapeutics’ 1-day share price return of 15.1% coming after sharp declines, including a 57.6% 30-day share price loss and a 50.4% 1-year total...
NYSE:SEMR
NYSE:SEMRSoftware

Semrush AI Push With Spotlight 2026 And ChatGPT Integration Under Adobe Deal

Semrush Holdings (NYSE:SEMR) has launched Spotlight 2026, an AI focused marketing conference centered on brand visibility in the AI search era. The company has introduced an official Semrush app within ChatGPT to bring its marketing toolkit into the conversational AI environment. These moves come as Semrush continues through its planned acquisition process with Adobe. Semrush operates as a digital marketing platform, with tools that help businesses manage search visibility, content, and...
NasdaqGS:ROOT
NasdaqGS:ROOTInsurance

Does Root’s (ROOT) Strong 2025 Results but Softer Q4 Profit Reframe Its Profitability Story?

Root, Inc. previously reported fourth-quarter 2025 revenue of US$397 million, up from US$326.7 million a year earlier, with net income of US$5.1 million compared with US$20.9 million. For 2025 overall, Root lifted revenue to US$1.52 billion and increased net income to US$38.3 million, but its fourth-quarter profit was lower than the prior year despite higher sales. Next, we’ll examine how Root’s higher full-year revenue and earnings, alongside weaker quarterly profit, may influence its...
NasdaqCM:HYMC
NasdaqCM:HYMCMetals and Mining

Hycroft Mining Reset Puts Larger Resources And Funding Needs In Focus

Hycroft Mining Holding (NasdaqCM:HYMC) reports a 55% increase in its gold and silver mineral resource base. The company eliminates all debt and shifts its focus from production to exploration and development. Hycroft launches its largest exploration drill program to date. The stock is added to the MSCI Small Cap Index, increasing its visibility with institutional investors. Hycroft Mining Holding, trading at $47.665, has gone through a major reset that is drawing fresh attention from the...
NYSE:YETI
NYSE:YETILeisure

New YETI CFO From Home Depot May Reshape Growth And Capital Choices

YETI Holdings (NYSE:YETI) has appointed Scott Bomar as its new Chief Financial Officer. Bomar joins the company from The Home Depot, bringing financial and operational leadership experience. He succeeds long serving CFO Mike McMullen, marking a key change in YETI's executive team. YETI Holdings, known for its premium coolers, drinkware and outdoor gear, sits at the intersection of consumer brands and the broader outdoor recreation and lifestyle market. For investors watching branded...
NasdaqGS:OMCL
NasdaqGS:OMCLMedical Equipment

Omnicell Leans Into Healthcare IT As ANiGENT Deal Reshapes Growth Story

Omnicell, ticker NasdaqGS:OMCL, is shifting its focus toward a software and services led model. The company recently acquired ANiGENT to deepen its capabilities in drug diversion detection within healthcare settings. This move marks a meaningful step in Omnicell's transition from a hardware vendor to a Healthcare IT company. Omnicell's pivot comes after a mixed share price record, with the stock at $41.53 and a value score of 4. The shares show a 9.8% gain over the past year, while longer...
NYSE:ACEL
NYSE:ACELHospitality

Accel Entertainment (ACEL) Margin Improvement Challenges Bears Focused On Concentration Risks

Accel Entertainment (ACEL) has wrapped up FY 2025 with fourth quarter revenue of US$341.4 million and EPS of US$0.19, capping a year in which trailing twelve month revenue reached US$1.3 billion and EPS came in at US$0.61. The company has seen quarterly revenue move from US$302.2 million in Q3 2024 to US$341.4 million in Q4 2025, while quarterly EPS stepped up from US$0.06 to US$0.19 over the same stretch, setting the backdrop for investors focused on earnings growth and profit consistency...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

CrowdStrike (CRWD) First Profitable Quarter Challenges Trailing Loss Narrative

CrowdStrike Holdings (CRWD) FY 2026 results in focus CrowdStrike Holdings (CRWD) has capped FY 2026 with fourth quarter revenue of about US$1.3 billion and basic EPS of US$0.15, alongside trailing twelve month revenue of roughly US$4.8 billion and a trailing basic EPS loss of US$0.65. The company has seen quarterly revenue move from US$1.06 billion in Q4 FY 2025 to US$1.31 billion in Q4 FY 2026, while basic EPS shifted from a loss of US$0.37 to a profit of US$0.15 over the same periods. For...
NasdaqCM:SSTI
NasdaqCM:SSTISoftware

SoundThinking (SSTI) Posts Q4 Loss As Margins Keep Bullish Turnaround Narratives Under Pressure

SoundThinking (SSTI) has just closed out FY 2025 with fourth quarter revenue of US$24.8 million and a basic EPS loss of US$0.22, capping a trailing twelve month run of US$104.1 million in revenue and a total EPS loss of US$0.74. Over the past year, the company has reported quarterly revenue between US$24.8 million and US$28.3 million, while quarterly basic EPS has ranged from a loss of US$0.12 to US$0.25. This sets up a results season in which investors may pay less attention to changes in...
NYSE:SF
NYSE:SFCapital Markets

Stifel 401(k) Lawsuit Raises Questions On Governance And Valuation Gap

A class action lawsuit has been filed against Stifel Financial Corp. alleging long term mismanagement of its 401(k) retirement plan. The suit claims the company failed to remove persistently underperforming investment funds, raising questions about its ERISA fiduciary practices. The litigation focuses on Stifel's role as a plan sponsor and its responsibilities to employees and plan beneficiaries. For investors tracking Stifel Financial (NYSE:SF), this lawsuit comes at a time when the stock...
NYSE:KVYO
NYSE:KVYOSoftware

Is Klaviyo (KVYO) Offering Value After A 51% One Year Share Price Slide

If you are wondering whether Klaviyo is starting to look attractively priced or still carries too much risk, the key question is what you are really paying for at the current share price of US$19.53. The stock has recently been volatile, with a 13.3% gain over the last 7 days, a 13.4% decline over the last 30 days, and a 33.4% decline year to date, while the 1 year return stands at a 51.5% decline. These swings have kept Klaviyo on many investors' watchlists as they weigh up how the market...